The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options. "With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life," Zydus Lifesciences said in a regulatory filing.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.